Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 4Gowling WLG (Canada) LLP

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

Gowling WLG (Canada) LLP

arrow
Pharmaconex
Not Confirmed

Gowling WLG (Canada) LLP

Country
arrow
Pharmaconex
Not Confirmed

Capmatinib Hydrochloride

Brand Name : TABRECTA

Patent Number : 2669991

Filing Date : 2007-11-19

Strength per Unit : 150mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-11-19

Date Granted : 2016-01-26

blank

02

Gowling WLG (Canada) LLP

arrow
Pharmaconex
Not Confirmed

Gowling WLG (Canada) LLP

Country
arrow
Pharmaconex
Not Confirmed

Capmatinib Hydrochloride

Brand Name : TABRECTA

Patent Number : 2724742

Filing Date : 2009-05-20

Strength per Unit : 150mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2029-05-20

Date Granted : 2016-07-19

blank

03

Gowling WLG (Canada) LLP

arrow
Pharmaconex
Not Confirmed

Gowling WLG (Canada) LLP

Country
arrow
Pharmaconex
Not Confirmed

Capmatinib Hydrochloride

Brand Name : TABRECTA

Patent Number : 2669991

Filing Date : 2007-11-19

Strength per Unit : 200mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-11-19

Date Granted : 2016-01-26

blank

04

Gowling WLG (Canada) LLP

arrow
Pharmaconex
Not Confirmed

Gowling WLG (Canada) LLP

Country
arrow
Pharmaconex
Not Confirmed

Capmatinib Hydrochloride

Brand Name : TABRECTA

Patent Number : 2724742

Filing Date : 2009-05-20

Strength per Unit : 200mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2029-05-20

Date Granted : 2016-07-19

blank